搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
13 天
HER2突变肺癌新希望!勃林格殷格翰创新肿瘤疗法Zongertinib效果显著
Beamion LUNG-1 Ib期研究达到了主要终点,研究数据显示,客观缓解率(ORR)为66.7%,这一结果由中央独立盲态审查(BICR)评估。[1] 在脑转移患者中也观察到初步疗效,颅内缓解率为33%,疾病控制率(DCR)达到74%。 Zongertinib 整体耐受性良好,主要为轻度且可控的治疗相关不良事件(TRAE),因毒性导致的停药率较低,仅为3%。 截至数据截止时,仍有三分之二的患者 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
今日热点
Left note, bail denied
Didn't authorize apology
1951 kidnap victim found
Returning Indian antiquities
Texas sues Biden admin
1/3 think they have CTE
Astronauts return to Earth
Robinson loses key staff
Makes emergency landing
Colo. shooter found guilty
No govt. shutdown for now
Closing last full-size store
Gulf Coast storm warning
Friedkin set to buy Everton
Reds fire manager
Visits US ammunition plant
NY reports death from EEE
Co-founder testifies
Asks to be put on NY ballot
FBI: Violent crime declined
More troops to Middle East
Dolphins legend Morris dies
Bulls escape MA rodeo
Economic speech this week
SpaceX plans Mars missions
Tech ban proposed
Trump's Pennsylvania rally
NE electoral change blocked
Free COVID-19 tests
California sues ExxonMobil
反馈